TIRZ-40

This product is intended for research purposes only

Tirzepatide 40 is a lyophilized research peptide that functions as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. This dual action sets it apart from traditional GLP-1 receptor agonists and has made it the subject of extensive research in the areas of metabolic function, weight management, and chronic disease prevention.

Key Research Areas & Studied Benefits

Weight Loss & Appetite Regulation
Tirzepatide has been shown in clinical and preclinical studies to significantly reduce body weight by enhancing satiety, delaying gastric emptying, and reducing overall food intake.

Blood Sugar Control & Insulin Sensitivity
Its ability to improve glycemic control makes it a valuable research candidate for studies involving type 2 diabetes, as it supports improved insulin response and reduction in A1C levels.

Cardiovascular Health
Emerging research has indicated Tirzepatide may contribute to reduced cardiovascular risk, including lower blood pressure, improved lipid profiles, and reduction in inflammatory markers, all of which are vital in heart disease prevention studies.

Liver Function & Fat Reduction
Some studies suggest Tirzepatide may reduce liver fat content, making it an important peptide for investigating nonalcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD).

Inflammation & Overall Metabolic Health
By addressing multiple metabolic pathways, Tirzepatide is also being evaluated for its broader impact on inflammatory markers, energy balance, and long-term disease prevention.